572 PYX-102, an anti-KLRG1 antibody, enhances cytotoxic activity of CD8-T-cells from PBMC and human tumor samples by blocking the interaction between KLRG1 and cadherins
Main Authors: | Ronald Herbst, Anthony Rodriguez, Kei Yasuda, Philipp Steiner, Liyang Diao, Jianwen Feng, Matthew Iovino, Sara Lewandowski, Dan Felitsky, Ben Keller, Ona Miller, Alyssa Quigley, Jan Pinkas |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
The Yin and Yang of Targeting KLRG1+ Tregs and Effector Cells
by: Samantha M. Borys, et al.
Published: (2022-04-01) -
The role of KLRG1: a novel biomarker and new therapeutic target
by: Yakun Zhang, et al.
Published: (2024-06-01) -
Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy
by: Xiaodong Yang, et al.
Published: (2021-06-01) -
Increased KLRG1 and PD-1 expression on CD8 T lymphocytes in TB-IRIS.
by: Odin Goovaerts, et al.
Published: (2019-01-01) -
Early primed KLRG1- CMV-specific T cells determine the size of the inflationary T cell pool.
by: Nicolas S Baumann, et al.
Published: (2019-05-01)